The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada

References

• Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94
   PubMed Web of Science ®Google Scholar
• World Health Organization. Atlas multiple sclerosis resources in the world. 2008. Availabel online at: http://www.who.int/mental_health/neurology/Atlas_MS_WEB.pdf. Accessed September 16, 2013
   Google Scholar
• Beck CA, Metz LM, Svenson LW, Patten SB. Regional variation of multiple sclerosis prevalence in Canada. Multiple Sclerosis 2005;11:516-19
   PubMed Web of Science ®Google Scholar
• Hurwitz BJ. The diagnosis of multiple sclerosis and the clinical subtypes. Ann Ind Acad Neurol 2009;12:226-30
   PubMed Web of Science ®Google Scholar
• Ebers GC. Natural history of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;71(Suppl 2):ii16-19
   PubMed Web of Science ®Google Scholar
• Zuvich RL, McCauley JL, Pericak-Vance MA, et al. Genetics and pathogenesis of multiple sclerosis. Semin Immunol 2009;21:328-33
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Multiple Sclerosis Trust. A to Z of MS: Expanded Disability Status Scale (EDSS). 2013. Available online at: http://www.mstrust.org.uk/atoz/edss.jsp, Accessed November 2013
   Google Scholar
• IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94
   PubMed Web of Science ®Google Scholar
• Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• Goldenberg MM. Multiple sclerosis review. P & T 2012;37:175-84
   PubMedGoogle Scholar
• Biogen Idec Canada. TECFIDERA™, formerly BG-12, provides a combination of proven efficacy and favourable safety profile. 2013. Available online at: http://www.newswire.ca/en/story/1142785/health-canada-approves-tecfideratm-as-a-first-line-oral-treatment-for-multiple-sclerosis. Accessed November 2013
   Google Scholar
• Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107
   PubMed Web of Science ®Google Scholar
• Microsoft Excel [computer software]. Redmond, WA; 2007. Available online at: https://products.office.com/en-us/excel. Accessed November 2013
   Google Scholar
• Statistics Canada. Projected population by age group and sex according to three projection scenarios for 2010, 2011, 2016, 2021, 2026, 2031 and 2036, at July 1 (2016). 2010. Available online at: http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/demo23c-eng.htm. Accessed November 2013
   Google Scholar
• Karampampa K, Gustavsson A, Miltenburger C, et al. Treatment experience, burden, and unmet needs (TRIBUNE) in multiple sclerosis: the costs and utilities of MS patients in Canada. J Populat Ther Clin Pharmacol 2012;19:e11-25
   PubMedGoogle Scholar
• Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27
   PubMed Web of Science ®Google Scholar
• Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value in Health: J Int Soc Pharmacoeconom Outcomes Res 2007;10:54-60
   PubMed Web of Science ®Google Scholar
• Gani R, Giovannoni G, Bates D, et al. Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK. PharmacoEconomics 2008;26:617-27
   PubMed Web of Science ®Google Scholar
• CADTH Therapeutic Review. Comparative Clinical and Cost-Effectiveness of Drug Therapies for Relapsing-Remitting Multiple Sclerosis. Vol. 1. Ottawa, ON: CADTH; 2013
   Google Scholar
• Chiao E, Meyer K. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis. Curr Med Res Opin 2009;25:1445-54
   PubMed Web of Science ®Google Scholar
• Dee A, Hutchinson M, De La Harpe D. A budget impact analysis of natalizumab use in Ireland. Irish J Med Sci 2012;181:199-204
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain J Neurol 1989;112:133-46
   Google Scholar